ArticleBMC cancer2020

Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).

Angela Damato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.